PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness
The Journal of Clinical Pharmacology · 2026
DOI: 10.1002/jcph.70271 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von André Dallmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bayer HealthCare SAS, Lille, France. Hauptthemen laut MEDLINE: Models, Biological, Maternal-Fetal Exchange, Pharmacokinetics, Fetus. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Physiologically based pharmacokinetic (PBPK) modeling has emerged as a critical tool for predicting fetal drug exposure during pregnancy, accounting for the complex interplay of maternal physiological changes and placental transfer mechanisms. This review summarizes the current state of PBPK modeling in maternal‐fetal pharmacology, discussing various modeling approaches, including compartmental structures and mathematical formulations for placental transfer, as well as approaches to parameterize placental drug transfer in humans. Furthermore, a regulatory perspective on the use of maternal‐fetal PBPK models in submissions to the MHRA is provided. Despite advancements, significant gaps remain in understanding the variability of placental drug transfer across gestational stages and the implications of transporter activity. Future research should focus on generating robust clinical data and integrating innovative technologies, such as organ‐on‐a‐chip systems, to enhance model accuracy. Additionally, regulatory acceptance of PBPK models will depend on the establishment of comprehensive validation frameworks. By fostering collaboration between researchers, clinicians, and regulatory bodies, PBPK modeling can advance toward safer therapeutic options for pregnant women and their developing fetuses, ultimately improving maternal‐fetal health outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bayer HealthCare SAS, Lille, France.
- Medicines and Healthcare products Regulatory Agency (MHRA), London, UK.
- ESQlabs GmbH, Saterland, Germany.
- Drug Delivery and Disposition Unit, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
- Certara UK Ltd (CPT Division), Sheffield, UK.
ORCID-Profile: André Dallmann, Andrew Butler, Sophie Fischer-Holzhausen, Essam Kerwash, Julia Macente, Karen Rowland Yeo, Jane Knöchel
Zitieren
APA
Dallmann, A., Butler, A., Fischer-Holzhausen, S., Kerwash, E., Macente, J., Nauwelaerts, N., Illamola, S. M., Rowland Yeo, K., & Knöchel, J. (2026). PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70271
Vancouver
Dallmann A, Butler A, Fischer-Holzhausen S, Kerwash E, Macente J, Nauwelaerts N, et al. PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70271
BibTeX
@article{Dallmann2026,
author = {Dallmann, André and Butler, Andrew and Fischer-Holzhausen, Sophie and Kerwash, Essam and Macente, Julia and Nauwelaerts, Nina and Illamola, Sílvia M and Rowland Yeo, Karen and Knöchel, Jane},
title = {PBPK Models for Fetal Drug Exposure: A Critical Assessment of Current Approaches and Regulatory Readiness},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/jcph.70271}
}
EUVIMED